During the recently held Southern California BioMedical Council (SoCalBio or SCBC) 10th Investor Conference, biotech firm Capricor Inc presented their Cardiosphere-derived Stem Cells or CDC technology, and the multi-billion dollar market potential for heart therapies using CDC.

"CDCs are the perfect stem cells to treat heart attacks and chronic heart failure" said Foellmer [President and CEO]. " Our stem cells are easily accessible from the patient themselves, readily grown in large numbers, and have proven themselves extremely safe. Unlike embryonic stem cells, there are no ethical or moral quandaries. And unlike other adult stem cells, such as bone marrow stem cells, our CDCs actually regrow cardiac muscle and vasculature. In short, CDCs have great potential for patients with a recent heart attack or chronic heart failure and we eagerly look forward to our imminent clinical trials."

Capricor Inc. is headquartered in Los Angeles, California, and specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. See their products currently under clinical trials.